Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: A Children's Oncology Group study

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4922-4928

  Horton, Terzah M ^a   Thompson, Patrick A ^a   Berg, Stacey L ^a   Adamson, Peter C ^a   Ingle, Ashish M ^a   Dolan, M Eileen ^a   Delaney, Shannon M ^a   Hedge, Madhuri ^a   Weiss, Heidi L ^a   Wu, Meng Fen ^a   Blaney, Susan M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW BIOPSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FEVER; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA RELAPSE; MALE; MICROSATELLITE INSTABILITY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; LEUKEMIA; MALE; MICROSATELLITE INSTABILITY; NEOPLASM RECURRENCE, LOCAL; TUMOR SUPPRESSOR PROTEINS;

EID: 36848999377     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0667     Document Type: Article

References (59)

1. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585-2597, 2000
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
3. Tentori L, Graziani G, Gilberti S, et al: Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 9:1888-1895, 1995
4. Messinger Y, Reaman GH, Ek O, et al: Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. Leuk Lymphoma 33:289-293, 1999
5. Seiter K, Liu D, Loughran T, et al: Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 20:3249-3253, 2002
6. Baer JC, Freeman AA, Newlands ES, et al: Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299-1302, 1993
7. Friedman HS, McLendon RE, Kerby T, et al: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857, 1998
8. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399, 2002
9. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
10. Pollack IF, Hamilton RL, Sobol RW, et al: O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 Cohort. J Clin Oncol 24:3431-3437, 2006
11. Taverna P, Catapano CV, Citti L, et al: Influence of O6- methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 3:401-405, 1992
12. Tentori L, Orlando L, Lacal PM, et al: Inhibition of O6- alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52:249-258, 1997
13. Esteller M, Hamilton SR, Burger PC, et al: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797, 1999
14. Costello JF, Futscher BW, Tano K, et al: Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 269:17228-17237, 1994
15. Balaña C, Ramirez JL, Taron M, et al: O(6)-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-Chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9:1461-1468, 2003
16. Esteller M, Gaidano G, Goodman SN, et al: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26-32, 2002
17. Rossi D, Capello D, Gloghini A, et al: Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89:154-164, 2004
18. Matsushita C, Yang Y, Takeuchi S, et al: Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 12:97-99, 2004
19. D'Atri S, Piccioni D, Castellano A, et al: Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Ann Oncol 6:389-393, 1995
20. Liu L, Markowitz S, Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56:5375-5379, 1996
21. Hangaishi A, Ogawa S, Mitani K, et al: Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines. Blood 89:1740-1747, 1997
22. Taverna P, Liu L, Hanson AJ, et al: Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 46:507-516, 2000
23. Gu L, Cline-Brown B, Zhang F, et al: Mismatch repair deficiency in hematological malignancies with microsatellite instability. Oncogene 21:5758-5764, 2002
24. Shen F, Decosterd LA, Gander M, et al: Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl 667:291-300, 1995
25. Rudek MA, Donehower RC, Statkevich P, et al: Temozolomide in patients with advanced cancer: Phase I and pharmacokinetic study. Pharmacotherapy 24:16-25, 2004
26. DiArgenio DZ, Schumitsky A: ADAPT II Users Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles, CA, Biomedical Systems Resource (version 4), 1997
27. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
28. Horton TM, Pati D, Plon SE, et al: A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group Study. Clin Cancer Res 13:1615-1622, 2007
29. Dolan ME, Roy SK, Fasanmade AA, et al: O6-benzylguanine in humans: Metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 16:1803-1810, 1998
30. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
31. Suraweera N, Duval A, Reperant M, et al: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123:1804-1811, 2002
32. Frazier ML, Sinicrope FA, Amos CI, et al: Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. Oncol Rep 6:497-505, 1999
33. Goel A, Arnold CN, Niedzwiecki D, et al: Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63:1608-1614, 2003
34. Estlin EJ, Lashford L, Ablett S, et al: Phase I study of temozolomide in paediatric patients with advanced cancer: United Kingdom Children's Cancer Study Group. Br J Cancer 78:652-661, 1998
35. Dhodapkar M, Rubin J, Reid JM, et al: Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093-1100, 1997
36. Hammond LA, Eckardt JR, Baker SD, et al: Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17:2604-2613, 1999
37. Brada M, Judson I, Beale P, et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022-1030, 1999
38. Reid JM, Stevens DC, Rubin J, et al: Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393-2398, 1997
39. Tisdale MJ: Antitumor imidazotetrazines: XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457-462, 1987
40. Gerson SL: MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307, 2004
41. Yeager ND, Dolan ME, Gastier JM, et al: O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma. J Pediatr Hematol Oncol 25:941-947, 2003
42. Nakayama K, Inokuchi K, Dan K: Hypermethylation of the putative tumor-suppressor genes DCC, p51/63 and O6-methylguanine-DNA methyltransferase (MGMT) and loss of their expressions in cell lines of hematological malignancies. J Nippon Med Sch 72:270-277, 2005
43. Pieper RO, Patel S, Ting SA, et al: Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J Biol Chem 271:13916-13924, 1996
44. Soejima H, Zhao W, Mukai T: Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 83:429-437, 2005
45. Levati L, Marra G, Lettieri T, et al: Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents. Genes Chromosomes Cancer 23:159-166, 1998
46. Ribeiro EM, Rodriguez JM, Coser VM, et al: Microsatellite instability and cytogenetic survey in myeloid leukemias. Braz J Med Biol Res 35:153-159, 2002
47. Kodera T, Kohno T, Takakura S, et al: Microsatellite instability in lymphoid leukemia and lymphoma cell lines but not in myeloid leukemia cell lines. Genes Chromosomes Cancer 26:267-269, 1999
48. Inokuchi K, Ikejima M, Watanabe A, et al: Loss of expression of the human MSH3 gene in hematological malignancies. Biochem Biophys Res Commun 214:171-179, 1995
49. Takeuchi S, Seriu T, Tasaka T, et al: Microsatellite instability and other molecular abnormalities in childhood acute lymphoblastic leukaemia. Br J Haematol 98:134-139, 1997
50. Reato G, Basso G, Putti MC, et al: Microsatellite analysis in childhood acute lymphoblastic leukemia. Haematologica 83:403-407, 1998
51. Krsková-Honzátková L, Cermak J, Sajdova J, et al: Microsatellite instability in hematological malignancies. Leuk Lymphoma 43:1979-1986, 2002
52. Ohyashiki JH, Ohyashiki K, Aizawa S, et al: Replication errors in hematological neoplasias: Genomic instability in progression of disease is different among different types of leukemia. Clin Cancer Res 2:1583-1589, 1996
53. Tasaka T, Lee S, Spira S, et al: Microsatellite instability during the progression of acute myelocytic leukaemia. Br J Haematol 98:219-221, 1997
54. Uehara E, Takeuchi S, Tasaka T, et al: Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int J Oncol 23:693-696, 2003
55. Das-Gupta EP, Seedhouse CH, Russell NH: Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol 114:307-312, 2001
56. Casorelli I, Offman J, Mele L, et al: Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2:547-559, 2003
57. Sheikhha MH, Tobal K, Liu Yin JA: High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 117:359-365, 2002
58. Olipitz W, Hopfinger G, Aguiar RC, et al: Defective DNA-mismatch repair: A potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer 34:243-248, 2002
59. Hatta Y, Yamada Y, Tomonaga M, et al: Microsatellite instability in adult T-cell leukaemia. Br J Haematol 101:341-344, 1998